Choi Jae Moon, Jo Jun-Young, Baik Jae-Won, Kim Sooyoung, Kim Chan Sik, Jeong Sung-Moon
Department of Anesthesiology and Pain Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Medicine (Baltimore). 2017 Jan;96(1):e5820. doi: 10.1097/MD.0000000000005820.
Preservation of adequate perfusion pressures to the graft is a main focus of intraoperative management during kidney transplantation. We undertook this study to investigate the incidence of the higher use of inotropes in kidney transplant recipients and identify the patient outcomes and preoperative and intraoperative variables related to this.We retrospectively analyzed 1053 patients who underwent kidney transplantation at Asan Medical Center between January 2006 and February 2012, stratified by their inotropic score ([dopamine] + [dobutamine] + [epinephrine × 100] + [norepinephrine × 100]) <7 versus ≥7, wherein all doses are expressed as μg/kg/min. We evaluated preoperative characteristics, hemodynamic parameters, and intraoperative variables as well as postoperative outcomes, such as length of hospital stay and 1-year rejection and mortality rate.Receiver-operating characteristic analysis was performed to determine inotropic score to predict 1-year mortality. An inotropic score of 7 had the best combined sensitivity and specificity. An inotropic score ≥7 (137 patients, 13.0%) was significantly more prevalent in older patients, those with polycystic kidney disease, and at a 2nd transplant. Anesthesia time, the amounts of crystalloid and 5% albumin infused, and the need for red blood cell transfusion were significantly higher in the inotropic score ≥7 group. The patients with a higher use of inotropes required longer postoperative hospital stay and experienced a >2-fold higher rejection within the 1st year and a 4-fold higher 1-year mortality rate.A higher use of inotropes in kidney transplant recipients is more prevalent in older patients, those with a 2nd transplant and in patients with polycystic kidney disease as their primary renal disease. The postoperative hospital stay, rejection within the 1st year, and 1-year mortality rate are increased in patients with an inotropic score ≥7.
维持移植肾充足的灌注压力是肾移植术中管理的主要重点。我们开展这项研究以调查肾移植受者中使用血管活性药物比例较高的发生率,并确定与此相关的患者预后以及术前和术中变量。我们回顾性分析了2006年1月至2012年2月在峨山医院中心接受肾移植的1053例患者,根据血管活性药物评分([多巴胺]+[多巴酚丁胺]+[肾上腺素×100]+[去甲肾上腺素×100])<7与≥7进行分层,所有剂量均以μg/kg/min表示。我们评估了术前特征、血流动力学参数、术中变量以及术后结局,如住院时间、1年排斥反应和死亡率。进行受试者工作特征分析以确定血管活性药物评分对预测1年死亡率的价值。血管活性药物评分为7时具有最佳的综合敏感性和特异性。血管活性药物评分≥7(137例患者,13.0%)在老年患者、多囊肾病患者以及再次移植患者中更为常见。血管活性药物评分≥7组的麻醉时间、晶体液和5%白蛋白输注量以及红细胞输血需求显著更高。血管活性药物使用比例较高的患者术后住院时间更长,在第1年内发生排斥反应的几率高出2倍以上,1年死亡率高出4倍。肾移植受者中血管活性药物使用比例较高在老年患者、再次移植患者以及以多囊肾病作为原发性肾病的患者中更为普遍。血管活性药物评分≥7的患者术后住院时间、第l年内的排斥反应以及1年死亡率均增加。